You haven't searched anything yet.
Overview
The Director, US Patient Services Marketing, Strategy & Innovation will be responsible for developing and executing on Alnylam's Patient Services strategy and tactics with a focus on the needs of patients currently enrolled in Alnylam Assist as well as future pipeline products and new indications. S/he will leverage all communication channels to drive an exceptional customer experience and reduce time-to-therapy for patients engaging with the service model for educational needs and/or initiating treatment with an Alnylam product. This individual will also lead the US Patient Services Marketing team, which is collectively responsible for creating and implementing strategies across Alnylam's protfolio to support patients/caregivers and HCP audiences. In close partnership with the TTR and Rare Brand Marketing teams, the Director of US Patient Services Marketing, Strategy & Innovation will identify additional educational opportunities across stakeholders in support of Alnylam's commercial business.
This position will report to the Senior Director, US Patient Services
Key Responsibilities
Qualifications
About Alnylam
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.
Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2022, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2023 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.
At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.
Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law. Alnylam is an E-Verify employer.
Full Time
$192k-244k (estimate)
05/02/2024
05/18/2024
alnylam.com
CAMBRIDGE, MA
1,000 - 3,000
2002
Public
MARK JOHNSON
$200M - $500M
Pharmaceutical
Alnylam is a biopharmaceutical company that develops RNA interference therapeutics for genetically defined diseases.